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Summary. Malaria is an infectious disease caused by the protist Plasmodium
spp. and it currently kills more than one million people annually. The burden of
malaria is concentrated in sub-Saharan Africa, India, and Southeast Asia. The par-
asite’s resistance to commonly used anti-malarial drugs has worsened the situation
in the poorest countries. The World Health Organization (WHO) estimates that
more than 100 countries suffer from endemic malaria episodes. In addition to
numerous control measures and treatments, several vaccines are at different
research stages and trials. We have assayed RTS,S/AS02A, a pre-erythrocytic can-
didate vaccine that has shown promising protection levels in phase IIb trials in
Mozambique. The vaccine is directed against the sporozoite form of the parasite,
which is injected by the mosquito Anopheles spp. The vaccine induces a strong
antibody response and stimulates Th1 cells—a subset of helper T cells that partic-
ipates in cell-mediated immunity. Recent interest by international funding agencies
has provided new inputs into initiatives and programs to fight malaria, which,
under normal welfare and adequate social development conditions, is a curable dis-
ease. [Int Microbiol 2006; 9(2):83-93]
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Introduction
Over the twentieth century, the worldwide area of land affect-
ed by malaria decreased from 54 to 27%. In spite of this
reduction, malaria remains a major global concern and one of
the most common illnesses affecting humankind [12]. It is
estimated that there are between 300 and 500 million clinical
cases per year. Data from the World Health Organization
(WHO) [28] show that 3000 million people, 50% of the
world’s population, live in malaria-risk areas. The disease
causes about one million deaths per year, 90% of which in
Africa, mostly children under five. The disease subsists in
more than 100 countries in different regions of the world,
including India, Southeast Asia, and Central and South
America, although sub-Saharan Africa is the most strongly
affected (Fig. 1). Efforts to reduce poverty and childhood
mortality in those vulnerable societies will fail if this devas-
tating disease is not adequately controlled. However, the
problem of controlling malaria in those countries is aggravat-
ed by inadequate health-care infrastructures and the precari-
ous socioeconomic conditions. The situation has become
even more complex over the last few years due to resistance
of the parasite (Plasmodium spp.) to commonly used anti-
malarial drugs, and to the emerging resistance of the vector
(the mosquito Anopheles spp.) to chemicals for controlling it. 
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To achieve a reasonable level of success in fighting
malaria, a well-designed attack is necessary using a combina-
tion of strategies. Recent political interests and initiatives are
providing renewed hope, which is being converted into
action through different programs and funding devoted to
fighting not only malaria but also several other diseases
[7,15]. Those and other approaches are absolutely necessary,
as well as the cooperation of the pharmaceutical companies.
It has been estimated that a minimum of US$ 3200 million
per year is needed to effectively control malaria, but only a
part of that sum is currently available [28].
The malaria literature is extraordinarily abundant.
Besides human beings, other species, including birds and pri-
mates, are also natural hosts of malaria parasites [22]. This
review will briefly provide a look at the historical and socio-
economic background of malaria, and offer a perspective of
the current initiatives and programs aimed at eradicating the
disease. The modus operandi of the malaria vector and para-
site as well as the features of the tested candidate vaccine
RTS,S/AS02A and other tools to prevent and fight the disease
will be examined. 
Historical background
Some historians have situated the beginnings of malaria as far
back as 10,000 years ago and even earlier. The establishment
of agriculture and farming created favorable conditions for
spreading the disease [19,24]. The increase in human popula-
tion density that followed the shift from a nomadic way of life
to a sedentary agricultural one that included the raising of cat-
tle may have provided adequate breeding places for anophe-
line mosquitoes [14]. Evidences from archaeological deposits
in the East Mediterranean date the disease to at least ca. 6000
years ago. Some ancient products used in the treatment of
malaria, which were remarkably effective, confirm the antiq-
uity of the disease. A drink prepared with qinghao (Artemisia
annua) has been used for at least 2000 years in China. The
active ingredient is artemisin, which only recently has been
chemically identified. Currently, artemisin is being consid-
ered to replace drugs such as chloroquine, which have become
useless due to resistance of the parasite [26]. 
References to malaria can be found in early Chinese,
Caldean, and Hindu writings. In the 4th century BC, malaria
was endemic in the Mediterranean basin. Fevers caused by
the proximity of humans to swamps and standing water were
noted by both the Greeks and the Romans, who established
the practice of draining swamps to control periodic fever
episodes. Despite the antiquity and morbidity of malaria, it is
unclear whether its fatality/lethality ratio was as high as in
modern times. During World War I, thousands of soldiers on
the Macedonian front were victims of malaria attacks. But,
curiously, this was not the case in the battle of Actium
(September, 31 BC) that confronted the Romans under the
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Fig. 1. Increasing burden of malaria and poverty. Malaria negatively affects the social and economic development
of societies. It is part of the vicious cycle of disease and poverty, since not only does poverty cause disease, but
disease causes poverty. (Based on “Tackle malaria today. Give tomorrow a chance”. Multilateral Initiative on
Malaria [http://www.mim.su.se].)
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leadership of Octavian (later Emperor Augustus), with the
Alexandrian army led by Mark Anthony and Cleopatra. The
battle involved about 400,000 soldiers, but there appear to
have been no losses due to malaria, although the disease
already existed. What was the reason for this? Some evidence
indicates that, by the fifth century AD, the malaria vector had
changed from a mild variety to another, much more aggres-
sive one. Therefore, it can be speculated that, had there been
a very efficient vector of malaria in Europe during antiquity,
Classic culture, with its impact on modern civilization world-
wide, would not have developed. 
Before discussing the systematic control of malaria, some
historical observations are necessary. The malaria parasite
was discovered in 1880 by Charles Louis Alphonse Laveran
(1845–1922), who found exflagellated gametocytes in a fresh
blood film obtained from a malaria patient. The work of
Ronald Ross (1857–1932) in India and Gianni Battista Grassi
(1854–1925) in Italy was also of great importance [5].
Working independently, both men described the life cycle of
the malaria parasite in birds and humans, respectively. In
1897, Ross showed that the mosquito was the vector of the
disease based on his observations of developing plasmodia in
the mosquito gut. At the same time, Grassi provided evidence
of the transmission of malaria from vectors to humans.
However, in 1902, only Ross was awarded the Nobel Prize in
Physiology or Medicine [11], “for his work on malaria, by
which he has shown how it enters the organism and thereby
has laid the foundation for successful research on this disease
and methods of combating it”. Controversy arose then—and
remains to the present day—about whether Ross or Grassi
was the first to discover the role of the mosquito in the trans-
mission of malaria. What is clear is that Grassi’s contribution
was as relevant as that of Ross, and that the Nobel
Commission, and even Ross, ignored his work [5]. In 1907,
Laveran was awarded the Nobel Prize for his work on the role
of protozoa in causing diseases, which was performed much
earlier than that of Ross and Grassi. Taken together, these dis-
coveries allowed the development of new control strategies.
The xenobiotic compound dichlorodiphenyltrichloroethane
(DDT) was introduced at the time of World War II [12]. The
discovery of the properties of this compound, which is very
effective in killing insects, earned Paul Müller the Nobel Prize
in Physiology or Medicine in 1948. Later, drugs of the chloro-
quine group were widely and effectively used against the par-
asite until resistance arose, first in South America and Asia
(1960s) and later in Africa (1980s). Significant actions for
controlling the disease included the US malaria eradication
program, which was set up in 1946 and managed by the
Communicable Disease Center (later renamed the Centers for
Disease Control, CDC) in Atlanta [www.cdc.gov]. Similar
actions were undertaken in Italy by the Istituto Superiore di Sa-
nità, located in Rome [www.iss.it], which from 1945 onwards
has concentrated efforts and resources to fighting malaria.
Consequences on social 
and economical development
Malaria is an infectious disease that, in addition to its health
consequences, has a large and tragic impact on the social and
economic development of societies. There is a close relation-
ship between malaria and poverty (Fig. 2). It is important to
understand that this is not a linear relationship but a vicious
cycle of disease and poverty, since not only does poverty
causes disease, but disease causes poverty. Malaria destroys
the capacities of individuals and hence the economic devel-
opment of their countries. Under this enormous burden, local
industries, such as those for the production and export of cof-
fee, vegetal oils, copper, cotton, and sugar, cannot become
commercially viable. The disease delays the development of
sub-Saharan African countries at a cost of at least US$
12,000 million per year [17]. The cumulative effect during
the last 35 years of this loss in growth means that the gross
domestic product of the African continent is 32% lower than
it would have been under healthy conditions.
Disease, parasite, and vector
The name of the disease derives from the Italian term for bad
air (mala aria). It has also been known as paludism (from
paludisme in French, paludo is wetland in Latin) and intermit-
tent fever, among other terms. Malaria is diagnosed by clinical
symptoms and microscopic examination of blood smears. The
accompanying symptoms, fever, shivering, pain in the joints,
and headache, quickly disappear after the parasite is killed by
anti-malarial drugs. In endemic regions, however, the parasites
have developed resistance to several commonly-used drugs.
Consequently, patients in those areas require treatment with
other, more expensive drugs.
The pathogenic mechanisms involved in the clinical illness
proceed along the following steps: (i) cyclic fever, the hall-
mark of the infection; (ii) anemia; (iii) tissue hypoxia, due to
anemia and alterations in the microcirculation of the blood;
and (iv) immunopathologic events, as malaria causes an in-
crease in circulating immunoglobulins [3]. Since the signs and
symptoms of anemia are non-specific, this disorder commonly
goes unrecognized. Hence the goal is a preventive, rather than
a curative approach, as this would reduce the impact of poor
access to health-care services. 
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Since 1638, malaria has been treated with quinine, an
alkaloid from the bitter bark of the South American quina-
quina tree (Cinchona ledgerian). The natives of Peru were
already aware of the anti-febrile properties of the tree before
the fifteenth century, and its use was extended to other South
American countries in the treatment of intermittent fevers.
The active ingredient, quinine, was first isolated in 1820. In
1945, another drug, chloroquine, a member of the quinolone
family, was found to be extremely effective for malaria pro-
phylaxis and treatment, preventing and virtually curing “jun-
gle” fever. However, nowadays, many strains of the parasite
have developed resistance to chloroquine and to other syn-
thetic drugs [26]. To treat malaria caused by those strains,
quinine is still used. Indeed, before the emergence of resist-
ance, the use of anti-malarial drugs and potent pesticides
directed against the vector had been quite successful in con-
trolling malaria in some countries. But the appearance of
drug-resistant strains and insecticide-resistant mosquitoes, as
well as the severe health and environmental problems caused
by the large-scale use of pesticides, prevented the eradication
of the disease. 
The parasite. Malaria parasites have a complex life cycle,
comprising sexual and asexual phases [26] that require the
succession of several developmental stages (Fig. 3). The par-
asite lives in humans for most of its life cycle, in the liver and
in erythrocytes. Intracellularly enclosed by a “parasitophorous”
vacuole in erythrocytes, the parasite reproduces asexually. In
recent years, more than 20 surface antigens have been charac-
terized by molecular techniques in Plasmodium spp. An inter-
esting feature of some of those antigens is that, very often, the
peptide regions have a repetitive structure [13]. 
Four species of apicomplexan protozoa cause malaria in
humans: Plasmodium falciparum, P. vivax, P. ovale, and P.
malariae. Aspects such as the molecular structure and cellu-
lar localization of putative target antigens, as well as the biol-
ogy of antigens by transfection of related parasites, have been
extensively studied for vaccine development [22]. P. falci-
parum is the causative agent of 90% of infections and is the
target of the vaccine trials of the different initiatives and pro-
grams. The genome sequence of P. falciparum was elucidat-
ed in 2002 [8]. The second most important causative agent is
P. vivax. In spite of the differences affecting appearance and
pathogenicity among the four species, their life cycles are
basically the same [14]. 
P. falciparum can develop in erythrocytes of people of all
ages, and parasitemia can reach very high levels. The infect-
ed erythrocytes break, releasing many new parasites (mero-
ALONSO
Fig. 2. Countries in which malaria is endemic and the current distribution of the disease. Malaria is present from
Central America through large areas of South America, Africa, India, Southwest Asia, and the Pacific Islands. The
most highly stricken area is sub-Saharan Africa, which accounts for more than 90% of all malaria deaths. Those
figures indicate the probability of dying before the age of five. In 2002 the world population exposed to malaria
was 48.30%, about 3000 million people. (Based on “Tackle malaria today. Give tomorrow a chance”. Multilateral
Initiative on Malaria [http://www.mim.su.se].)
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zoites) that then infect more erythrocytes; ultimately, this
leads to the destruction of massive numbers of red blood
cells. The characteristic chills and fever, or paroxysm, asso-
ciated with malaria occur when the parasites are released
from the erythrocytes, and since release of the parasites is
periodic, paroxysms are also periodic. 
Sporozoites from the mosquito salivary gland are inject-
ed into the human while the mosquito injects anticoagulant
saliva to ensure an even-flowing blood meal. Once in the
bloodstream, the sporozoites reach the liver and penetrate
hepatocytes, where they remain for 9–16 days, multiplying
within the hepatic cells. On release, they return to the blood-
stream and penetrate erythrocytes, in which they produce
either merozoites or micro- and macrogametocytes, which
have no further activity within the human host. Another mos-
quito arriving to feed on the blood may suck up these game-
tocytes into its gut, where exflagellation of microgameto-
cytes occurs, and the macrogametocytes are fertilized. The
resulting ookinete penetrates the wall of a cell in the midgut
of the insect, where it develops into an oocyst. By sporoge-
ny, this oocyst produces many sporozoites; when the oocyst
ruptures, the sporozoites migrate to the salivary gland of the
vector for injection into another human host. A biting female
mosquito transfers about 10% of its sporozoite load into the
capillaries or perivascular tissue of the host. The sporozoites
must then begin their evasion of host defenses, possibly by
“camouflaging” themselves with binding proteins from the
host serum. Some sporozoites are destroyed by macrophages
or by antigen-specific antibodies in immune individuals, but
in non-immune individuals they reach the hepatocytes and
initiate schizogeny or become hypnozoites, depending on
their delay trigger. All sporozoites leave the peripheral circu-
lation within 45 min [27].
The vector. Malaria is a vector-borne disease spread by
the bite of the female Anopheles mosquito, a genus of the
group Anophelines. Although the mosquito is always the vec-
tor, out of the 380 species of Anopheles only 60 transmit
malaria parasites, and only the females do, as the males do
not feed on blood. Anophelines breed in water, like most
other mosquitoes. Each species has its preferred breeding
grounds and feeding pattern. Usually, breeding sites are for-
est pools, irrigated fields (rice fields, for instance), lakes, and
temporary rainwater puddles. Their sensitivity to insecticides
MALARIA VACCINE
Fig. 3. Life cycle of Plasmodium. In the history of humankind, infectious diseases have played significant roles in wars, and have tragi-
cally brought about the intermediate or final fate of many conflicts. Those numberless armies of men and other animals, transporting mate-
rials and weapons, succumbed in the face of attacks by unexpected and invisible enemies: infectious diseases, with malaria being one of
the most frequent. (Based on “Scheme of the life cycle of malaria”. Centers for Disease Control and Prevention (CDC)
[http://www.cdc.bov/malaria/biology/life_cycle.htm].)
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is highly variable, and adaptation of some anophelian species
to urban environments has been reported [16].
Climatic factors, such as temperature, humidity, and rain-
fall, are key determinants in the distribution of malaria. In
tropical and subtropical areas, the climatic conditions are
optimal to allow the survival and multiplication of the mos-
quitoes. To transmit malaria effectively, female Anopheles
must survive long enough after they have become infected
through a blood meal from an infected human. Temperature
is most significant, since below 20°C the parasite cannot
complete its growth cycle inside the mosquito. Collections of
water following rainfall are also breeding sites where
Anopheles eggs are deposited and larvae develop into adults
in a process that approximately takes 9–12 days. 
The Global Malaria Eradication Campaign, an important
program led by WHO, was started in 1955 and its aim was
the worldwide eradication of malaria. However, those efforts
were gradually abandoned from 1969 to 1976 due to the real-
ization that the objective was unlikely to be ever achieved.
Although large areas of the world were successful in control-
ling the disease, this was not the case for developing coun-
tries. The resistance of the vector to DDT and the resistance
of strains of Plasmodium falciparum to chloroquine severely
impaired the WHO program. 
Strategic programs and initiatives 
Anti-malarial chemoprophylaxis in endemic areas of Africa
was shown to reduce malaria morbidity, but it was abandoned
due to the growing threat posed by resistance of the parasite.
This remains an acute problem for drugs that have been used
in the treatment of the infection and is a prominent factor
explaining the increase in mortality [26]. Chloroquine is inef-
fective in most parts of Africa and the efficacy of sulfadoxine-
pyrimethamine, which replaced it, is decreasing due to the
appearance of resistant strains. Drug resistance causes treat-
ment failure and can lead to death and the further, rapid
spreading of resistance. New hope has been offered by
artemisin derivatives, which are effective in combination with
other anti-malarials. Nevertheless, the success of this
approach has been limited by the poor supply of high-quality
artemisin derivatives and by their high cost. The WHO cur-
rently recommends artemisin-class combination therapies
(ACTs) for the treatment of malaria, since the benefits of com-
bined therapy include a delay in the appearance of resistance
[2]. However, the high price of ACTs remains problematic.
The deployment of existing “weapons” on a vastly
greater scale is required to fight malaria, together with the
improvement of those weapons and the development of new
ones. This is in fact true for most infectious diseases, which
mainly occur in poor regions of the world (21). In-depth
knowledge not only of the pathogenesis of malaria but also
of the economic and social conditions of those countries
where the disease is endemic is necessary to design effective
treatment strategies. Vaccines are well-suited for resource-
poor settings, and insecticide-treated bednets with long-act-
ing insecticides are suitable for rural zones in Africa. Also,
funds are needed to provide drugs, logistics, and health-care
services in most endemic areas.
Currently, three major tools are used to control malaria: (i)
control of mosquitoes, (ii) reduction of human–vector contact,
and (iii) prevention and treatment of the disease with drugs
[15]. Vector control includes indoor residual spraying, man-
agement to eliminate breeding sites, and treatment to eliminate
mosquito larvae with appropriate larvicides. Nevertheless,
while those practices have effectively saved millions of lives
worldwide, their high cost and complexity make them difficult
to implement in rural areas of sub-Saharan Africa. The reduc-
tion of human-vector contact through insecticide-treated bed-
nets has much better acceptance and suitability; but, although
they are inexpensive and effective, less than 2% of Africans
sleep under them. Thus, the future of malaria control requires
the development of vaccines and the availability of effective
and inexpensive drugs. As part of the search for new means
of control, international initiatives like the Intermittent
Preventive Treatment in infants (IPTi) [http://www.ipti-malaria.
org] are offering new approaches.
IPTi is a promising strategy in the fight against malaria.
Infants receive an anti-malarial drug three times during their
first year of life. This practice has been shown to reduce
malaria and anemia in infants less than 1 year of age by up to
60% [21], and it seems that IPTi could become a major tool
for malaria control in Africa. IPTi can be delivered through
the Expanded Programme on Immunization (EPI): [http://
www.wpro.who.int/sites/epi/overview.htm], which is one of
the best-functioning systems of regular health contact with
young children in Africa. 
Besides the aforementioned, some other actions and pro-
grams currently working on malaria are: 
Malaria Vaccine Initiative (MVI) was created in 1999
by a grant from the Bill & Melinda Gates Foundation. MVI
works with government, industry, and academic partners on
five continents within PATH (Programme for Appropriate
Technology in Health), a world-wide nonprofit organization:
[http://www.malariavaccine.org]. Its mission is to accelerate
the development of malaria vaccines and ensure their avail-
ability for developing countries. 
The candidate RTS,S/AS02A vaccine is being developed
and tested under the auspices of The Global Health Program,
ALONSO
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which is also financed by the Bill & Melinda Gates Founda-
tion: [http://www.gatesfoundation.org/GlobalHealth].
Roll Back Malaria (RBM) is a global partnership to
develop and coordinate strategies and interventions against
malaria: [http://www.rbm.who.int]. It aims at halving malar-
ia deaths by 2010, and halving them again by 2015.
The Global Fund to Fight AIDS, Tuberculosis and
Malaria is a partnership between governments, civil society, the
private sector, and affected communities to support interven-
tions against all three diseases: [http://www.theglobalfund.org].
The Multilateral Initiative on Malaria (MIM) supports
international collaboration and co-operation in scientific
research on malaria: [http://www.mim.su.se]. 
These initiatives and programs, among others, are work-
ing alone or in combination to offer new hopes of achieving
the objective of controlling malaria. Nevertheless, the finan-
cial and human efforts and resources need to be continuous. 
The RTS,S/AS02A vaccine
Vaccine development is a long process that takes years of
clinical testing and trials until licensing and public availabil-
ity are reached. Attempts to develop a malaria vaccine began
more than 50 years ago. Some of the developed vaccines
showed promising results [9,23,25], such as the candidate
vaccine developed in Colombia by Manuel Patarroyo, Spf66.
Nevertheless, a lack of consistency with other trials [6,18],
the failure to prevent malaria in infants [1], and difficulties in
product availability and reproducibility stopped further
development of this vaccine [10]. 
The partnership formed between MVI-GSK (produced by
GlaxoSmithKline), the Centro de Investigação em Saúde da
Manhiça (CISM), the Mozambique Ministry of Health, the
Bill & Melinda Gates Foundation, and the Hospital Clínic de
Barcelona has been involved in the development and assay of
the candidate vaccine RTS,S/AS02A, which was specifically
designed to prevent infection by P. falciparum. The vaccine
is directed against the sporozoite, the form of the parasite that
is injected by mosquitoes. After immunization, antibodies and
white blood cells are produced that can prevent the sporozoite
from either surviving or developing further in the liver. 
Our team has successfully tested RTS,S/AS02A in a
phase IIb trial that was conducted in children age 1–4 years
in Mozambique, where malaria is endemic. The results were
clearly the best that have ever been obtained with a candidate
malaria vaccine. The findings were very encouraging: the
vaccine induced a strong antibody response, stimulated Th1
cellular immunity, and showed efficacy against clinical
malaria. However, further trials will be needed to prove that
the vaccine is safe and effective before a license can be granted.
This goal will probably be achieved by 2010.
Development of the vaccine
We have been involved in the development of RTS,S/AS02A
since 2000. The vaccine’s target is the protein of the circum-
sporozoite on the sporozoite of P. falciparum. The repetitive
sequences of the protein have long been considered as a target
for a potential vaccine. RTS,S is a hybrid molecule expressed
in yeast by recombination, in which the circumsporozoite
protein, central tandem repeat, and carboxyl-terminal region
are fused to the N terminal of the S-antigen of hepatitis B
virus in a particle that also includes unfused S-antigen [3]. It
is assumed that the adjuvant used in the vaccine, AS02A,
which is an oil in water emulsion with the immunostimulant
monosphophoryl lipid A, has been essential to improving the
viability of this vaccine. 
The relevance of an adjuvant—an area of intensive
study—lies in the fact that pairing a malaria antigen with the
adequate vaccine adjuvant greatly contributes to the ability of
the vaccine to trigger a strong immune response. Other trials,
including those with RTS,S, have used conserved circum-
sporozoite protein fragments as a vaccine, but without suc-
cess. The change came with the addition of this new adju-
vant. It was known that this protein induced good titers of
antibodies and cellular responses, as measured by the pro-
duction of γ-interferon and by cytotoxic reactions. Protection
evidence came from experimental challenge models in a trial
conducted in the USA. In that study, the development of
infection was monitored in healthy volunteers who had been
previously immunized with the vaccine and who were subse-
quently challenged with the parasite. 
Good profiles of safety and immunogenicity of the prod-
uct were confirmed in phase I studies in Gambian children
and adults [4] and in Mozambican children. This initial suc-
cess allowed us to start a phase IIb, proof-of-concept effica-
cy trial in Mozambique. This trial estimated the immuno-
genicity, safety, and efficacy of the vaccine as determined by
the prevention of malaria episodes [3]. The trial, results and
comments were published in The Lancet in October 2004 [3].
Here we include some additional comments, results, and pro-
cedures of that trial based on the lectures and interviews we
gave after publication of our work. It is our intention to
attract the interest of the general public, institutions, and sci-
entific community in the fight against malaria.
One of the greatest problems with malaria, which
accounts for the extreme difficulty of developing a vaccine,
is that we do not yet understand how individuals develop
MALARIA VACCINE
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immunity against the disease. Since the work of Koch on
Java Island at the end of the 19th century, it has been known
that adults who survive malaria infection acquire a highly
effective immunity, but the mechanisms involved and how
they operate remain unknown, as is the role of indirect pro-
tective measures. Tishkoff et al. [24] stated that, throughout
human evolution, genetic defense mechanisms have arisen in
regions where malaria is prevalent, and that most human
genes that reduce the risk of malaria infection are expressed
in erythrocytes. Nonetheless, little is known about the immu-
nity that offers protection against malaria, nor is it at all clear
which proteins are responsible for protection. Animal mod-
els, including rats, chimpanzees, and rhesus monkeys, are not
useful for studying malaria in humans. Thus, the only way to
assess whether a vaccine is effective is by conducting clini-
cal trials in natural conditions. In hepatitis B, for instance, it
is known that people who have a certain threshold level of anti-
bodies against the viral surface antigen are protected. Thus, for
hepatitis B, individuals must be immunized and then after 20
or 30 days antibody titers must be measured. The same pro-
cedure is used for diphtheria, tetanus, pneumococcus, and
several other infectious diseases, but not malaria. 
The geographical and 
sociological context
Mozambique is one of the poorest countries in the world.
Manhiça, in the southern part of the country, is a district of
Maputo province. The vaccine trial was carried out in the
CISM, where the demography department is in charge of
geographically delimitating the study area, mapping it,
geopositioning each house using GPS, and registering the
population in a census. We often start our papers saying that,
in Africa, most people are born and die without ever being
registered; and this is true. There are no direct measures of
mortality. In the study area, we registered the population,
which currently is around 70,000. Births, deaths, emigra-
tions, immigrations, pregnancies, and changes of residence
were registered periodically in our census, which provided a
powerful research tool (Fig.4).
In the Manhiça region, malaria transmission takes place
throughout the year. P. falciparum is the most common
species and Anopheles funestus is the main vector. The ento-
mological inoculation rate for 2002 was 38 infective bites per
person/year. In Ilha Josina, 55 km north of Manhiça, we esti-
mated that people received between one and two bites per
day. Those figures reflect the high rates of transmission,
which are also evidenced by the fact that malaria is the main
cause of hospitalization and death in children under the age
of five. The situation is quite representative of what happens
in sub-Saharan Africa and in most of the African continent.
In Manhiça and Ilha Josina, we undertook the last proof-of-
concept trial in children age 1–4 years. The primary objective
was to evaluate the efficacy of the vaccine as measured by
the number of clinical episodes of malaria caused by P. falci-
parum. Clinical episodes were defined by an axillary temper-
ature of ≥37.5ºC and parasitemia (presence of the asexual
stage of P. falciparum in the peripheral blood at a concentra-
tion higher than 2500 parasites per microliter). Since not
everybody infected with the parasite presents with a clinical
episode of malaria, we looked for indicators that better
defined clinical episodes when the prevalence of infection is
high. This was important because, in the absence of specifici-
ty, the results become biased towards zero.
The vaccine trial
The trial was designed to assess the efficacy at two stages in
the life cycle of P. falciparum and the pathogenesis of malaria:
clinical disease and infection. Each outcome was measured
simultaneously in two cohorts based in different sites:
Manhiça (cohort 1) and Ilha Josina (cohort 2). The study was
a phase IIb, double-blind, randomized controlled trial. Three
intramuscular doses of either RTS,S/AS02 vaccine or a con-
trol vaccine (not placebo) were administered at 0, 1, and 2
months, that is with a 30-day interval. As control vaccine,
hepatitis B was administered to children older than 24
months. Children younger than 24 months received pneumo-
coccal vaccine (2 doses) and Haemophilus influenzae vac-
cine (1 dose). This procedure ensured that the study remained
double-blind. The trial began in April 2003 and the double-
blind phase ended on May 30, 2004. The opening of the code
and the analysis were done during the first week of August
2004, according to an analytical plan previously decided,
closed, and submitted to the U.S. Food and Drug
Administration (FDA). The results were published in The
Lancet in October 2004 [3]. 
Cohort 1 (Manhiça), with 1600 children age 1–4 years,
received three vaccine doses with intervals of 30 days.
Cohort 2 (Ilha Josina), with 417 children, also received the
vaccine at 30-day intervals, but peripheral parasitemia was
cleared with anti-malarial drugs between the second and third
dose in order to assess the efficacy of the vaccine in reducing
new infections. Thus, the two groups allowed us to ascertain
the answers to the following questions: What is the efficacy
of the vaccine against clinical episodes of malaria (passive
surveillance)? What is its efficacy against new infections
(detected through a combination of active and passive sur-
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veillance)? Once the correct random allocation was checked,
after the code was broken, and the comparability of the two
groups was ensured, any difference found could be attributed
to the vaccination and not to the introduction of confounding
factors (Table 1). 
The state of the art: 
the vaccination results
Severe adverse events. These were defined as any hos-
pital admission by any cause and their numbers were higher in
the control group (249) than in the RTS,S/AS02A group (180).
Fifteen children died, 10 in the control group and 5 in the
RTS,S/AS02A group. Assuming the mortality rate at this age
in that location, between 35 and 40 deaths would have been
expected. A reduction in mortality often occurs during a study
due to the fact that the participants are being closely followed.
In the control group, four deaths were specifically attributed to
malaria. Also, there were three episodes of cerebral malaria in
the control group but none in the vaccine group.
Immunogenicity. Anti-circumsporozoite (the part of the
P. falciparum protein included in the vaccine) antibodies and
antibodies against the hepatitis B surface antigen were evalu-
ated. Geometric mean titers of anti-circumsporozoite antibod-
ies for children younger or older than 24 months were
obtained. The same was done for antibodies against surface
antigen of hepatitis B. It was remarkable that there was good
production of antibodies against the conserved region of the
circumsporozoite. Production increased from 0.3 at baseline
to 273 one month after the third dose in children younger than
24 months, and from 0.3 to 158 in children older than 24
months. There was some evidence that antibody titers were
greater in small children, as the vaccine seems to be more
immunogenic in children younger than 24 months. Although
antibody kinetics fell, six months after the third dose the high
titers persisted. High levels of anti-hepatitis B surface antigen
antibodies were also produced. Antibodies increased from 63
at baseline to 51,000 one month after the third dose in children
less than 24 months and from 9 to 11,000 in children older
than 24 months, which again shows greater immunogenicity
in children younger than 24 months. Another interesting result
was that the antibody titers against hepatitis B surface antigen
induced by RTS,S/AS02A vaccine were higher than those
induced by the existent hepatitis B vaccine.
Efficacy. In Manhiça, during the first 6 months of follow
up, 123 first clinical episodes of malaria occurred in the
RTS,S/AS02A group, compared to 159 in the control group
(Table 1). Incidence rates were 0.38 versus 0.52, respective-
ly, which gives an estimation of vaccine efficacy of 29.9%,
(confidence intervals 11.0–44.8, p < 0.004). Vaccine efficacy
was assessed with Cox regression models; Schoenfeld resid-
uals and time-dependent Cox models were used to investi-
gate the proportional hazards assumption. Consistent with
this efficacy estimate at the cross-sectional survey 6 months
after the third dose, the prevalence of infection was 37%
lower in the RTS,S/AS02A group than in the control group.
Estimates of RTS,S/AS02A efficacy with respect to other
endpoints, including first episode of fever and any level of
P. falciparum parasitemia, first episode of fever or history of
fever and P. falciparum parasitemia, first episode of fever
and P. falciparum parasitemia with more than 15,000 para-
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Fig. 4. Malaria-affected population, from the mid nineteenth century to the down of the twenty-first century. Left, La Malaria (1850–1851), oil canvas by
Antoine August Ernest Hébert (1817–1908). Right, waiting for the doctor at the health facilities in Vilha Josina Island, Manhiça district, Mozambique. 
92 INT. MICROBIOL. Vol. 9, 2006
sites/microliter, were most of them around 30%, and all of
them were statistically significant. The efficacy of the vaccine
against episodes of severe malaria was assessed. Severe
malaria, defined according to WHO criteria, included a com-
posite of severe anemia (hematocrit < 15%), cerebral malaria
(Blantyre coma score < 2), generalized convulsions, prostra-
tion, hypoglycemia (< 2.2 mmol/dl), acidosis, or circulatory
collapse. In the control group, 26 cases of severe malaria were
reported versus 11 in the RTS,S/AS02A group, which pro-
vides an efficacy of 57.7% (p < 0.019). Exploratory analysis
led to an estimate of vaccine efficacy in children under 24
months of 76.9% ( p < 0.018). Finally, no correlation was
found between titers of antibodies to circumsporozoite and
protection. 
In Ilha Josina, where transmission is very intense, the
time to first infection was determined and resulted in an esti-
mated efficacy of 45% in the prevention of new infections
(confidence intervals 31.4–55.9, p < 0.0001). In summary,
the RTS,S/AS02A malaria vaccine was shown to be safe and
well-tolerated when administered for the first time to chil-
dren 1–4 years old living in endemic zones. The vaccine
showed a high degree of immunogenicity against both cir-
cumsporozoite protein and hepatitis B. The efficacy in delay-
ing time to first infection was 45%. Vaccine efficacy for the
first clinical episode was 30%, and for severe malaria 58%.
Children younger than two years presented higher immuno-
genicity and efficacy. All our data suggest that efficacy lasts
at least during the first 6 months.
Trial participants are still under surveillance to evaluate
whether efficacy is maintained during the following year.
[The following phase of the vaccination assay was performed
as initially scheduled and the results confirmed the levels of
protection by at least 18 months. Published in The Lancet,
Nov. 15, 2005, online edition.]
Clearly, delaying time to new infections means that not
only is there a reduction of new infections but also of new
episodes of mild and complicated malaria. This is a novelty
that opens unexpected, important doors. Nevertheless, an
immunological surrogate to correlate with protection is lack-
ing. From the public health point of view, these are very
important results. Due to the extraordinary antigenic com-
plexity and cycle of the malaria parasite, it is naive to think
there will be a malaria vaccine with 100% efficacy. Never-
theless, the availability of a vaccine with nearby 60% effica-
cy, if administered in combination with other available control
tools, could play a critical role in controlling the disease. 
For many years, the difficulty or even impossibility to
develop a vaccine against malaria has been well known. All
researchers involved in the fight against this disease agree
that it is an strenuous task. But there is no place for hopeless-
ness. In view of our results, we can conclude that a vaccine
against malaria can be developed, although continuous
efforts and resources, as well as a high level of confidence
are needed to pursue promising trials and initiatives. 
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Table 1. Vaccine efficacy
Control vaccine RTS,S/AS02A
Events Pyear Rate Events Pyear Rate Vaccine efficacy (95% CI) p
Clinical malaria (cohort 1)
First episode of fever and parasitaemia > 2500 per μl   
First episode of fever and parasitaemia > 0 per μl  
First episode of fever or history of fever and 
pasasitaemia > 0 per μl
First episode of fever and parasitaemia > 15 000 per μl
First episode of fever and parasitaemia 100 000 per μl
Multiple episodes of fever and 
pasasitaemia > 2500 per μl
159
176
251
138
44
190
302.9
300.5
284.3
307.08
324.9
330.1
0.52
0.59
0.88
0.45
0.14
0.58
123
137
188
104
40
153
321.6
318.1
309.0
324.5
335.3
341.0
0.38
0.43
0.61
0.32
0.12
0.45
29.9% (11.0 to 44.8)
28.6% (10.4 to 43.1)
33.8% (19.7 to 45.3)
31.7% (11.5 to 47.2)
16.4% (–29.1 to 45.9)
27.4% (6.2 to 43.8)
0.004
0.004
<0.0001
0.004
0.419
0.014
Malaria infection (cohort 2)
First episode of parasitaemia > 0 per μl 166 25.9 6.42 157 45.0 3.49 45.0%  (31.4 to 55.9) <0.0001
Notes:
Pyear = person-year at risk.
Vaccine efficacy estimates adjusted by age at baseline, bednet use at baseline, distance from health facility, and geographical region.
Reprinted from The Lancet, vol. 364, Alonso PL, Sacarlal J, Aponte JJ, et al, Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum
infection and disease in young African children: randomised controlled trial, pp. 1411-1420. Copyright (2004), with permission from Elsevier.
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MALARIA VACCINE
La malaria: preparación de una vacuna
(RTS,S/AS02A) para un antiguo azote 
de la humanidad
Resumen. La malaria, una enfermedad infecciosa causada por el protista
Plasmodium spp. causa anualmente más de un millón de muertes. Las regiones
más afectadas son África subsahariana, India y el sudeste asiático. La resisten-
cia del parásito a los fármacos antimaláricos más comunes ha empeorado la
situación en los países más pobres. La Organización Mundial de la Salud
(OMS) calcula que son más de 100 los países donde la enfermedad es endémi-
ca. Además de las numerosas medidas de control y de los tratamientos a los
afectados, varias vacunas se encuentran en diferentes fases de prueba. Nuestro
grupo ha ensayado la RTS,S/AS02A, una vacuna candidata pre-eritrocítica
que ha dado niveles de protección esperanzadores en ensayos de fase IIb en
Mozambique. La vacuna está dirigida contra el esporozoito, la forma del
parásito inyectada por el mosquito Anopheles spp. La vacuna induce una
fuerte producción de anticuerpos y células Th1 (el tipo de células T que inter-
vienen en la inmunidad mediada por células). El reciente interés de organiza-
ciones internacionales patrocinadoras ha supuesto un renovado estímulo a ini-
ciativas y programas para combatir la malaria, una enfermedad curable en
condiciones adecuadas de desarrollo social. [Int Microbiol 2006; 9(2):83-93]
Palabras clave: Plasmodium spp. · Anopheles spp. · malaria · vacuna
antimalaria pre-eritrocítica · vacuna antimalaria RTS,S/AS02A
A malária: preparação de uma vacina
(RTS,S/AS02A) para um antigo flagelo 
da humanidade
Resumo. A malária, uma doença infecciosa causada por o protista Plasmo-
dium spp. causa anualmente mais de um milhão de mortes. As regiões mais
afectadas são África subsaariana, Índia e o sudeste asiático. A resistência do
parasita aos fármacos antimaláricos de uso mais comum piorou a situação
nos países mais pobres. A Organização Mundial da Saúde (OMS) calcula
que são mais de 100 os países onde a doença é endémica. Além das nume-
rosas medidas de controle e dos tratamentos aos afectados, estão a desen-
volver-se vacinas, cujo ensaio se encontra em diferentes fases. O nosso
grupo ensaiou a RTS,S/AS02A, uma vacina candidata pre-eritrocítica que
deu níveis de protecção esperançadores em ensaios de fase IIb em
Moçambique. A vacina está dirigida contra o esporozoito, a forma do para-
sita injectada pelo mosquito Anopheles spp. A vacina induz uma forte pro-
dução de anticorpos e células Th1 (o tipo de células T que intervêm na imu-
nidade mediada por células). O interesse recente de organizações internacio-
nais patrocinadores supôs um estímulo renovado a iniciativas e programas
para combater a malária, uma doença curável em condições adequadas de
desenvolvimento social. [Int Microbiol 2006; 9(2):83-93]
Palavras chave: Plasmodium spp. · Anopheles spp. · malária · vacina
antimalária pre-eritrocítica · vacina antimalária RTS,S/AS02A
